Company Encyclopedia
View More
name
Otsuka Pharmaceutical
OTSKY.US
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement instruments, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, and insecticide and toiletry products.
4.359 T
OTSKY.USMarket value -Rank by Market Cap -/-

Financial Score

14/11/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking10/180
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE16.73%A
    • Profit Margin18.57%A
    • Gross Margin71.64%A
  • Growth ScoreB
    • Revenue YoY5.37%C
    • Net Profit YoY192.97%A
    • Total Assets YoY5.29%B
    • Net Assets YoY9.72%B
  • Cash ScoreC
    • Cash Flow Margin538.52%C
    • OCF YoY5.37%C
  • Operating ScoreB
    • Turnover0.64B
  • Debt ScoreB
    • Gearing Ratio26.11%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Otsuka (OTCMKTS:OTSKY) Shares Cross Below 50 Day Moving Average - Here's Why

    Otsuka Holdings Co., Ltd. (OTCMKTS:OTSKY) shares fell below the 50-day moving average of $27.39, trading as low as $26.62. Analysts have upgraded the stock from "strong sell" to "hold." Despite the hold rating, top analysts suggest better investment opportunities elsewhere. Otsuka operates in pharmaceuticals and other sectors globally.

    Market Beat·
    US
    OTSKY
    0.00%
    Market Beat·
    US
    OTSKY
    0.00%

    4D Molecular Therapeutics' Q3 revenue misses

    4D Molecular Therapeutics reported Q3 revenue of $90,000, missing analyst expectations of $287,900. The net income also fell short at -$56.88 million compared to the expected -$56.20 million. The company has entered a strategic partnership with Otsuka, receiving $85 million upfront, which is expected to support its cash runway into the second half of 2028. The average analyst rating remains a 'buy' with a 12-month price target of $34.50, reflecting a potential upside of 69.6% from its recent closing price of $10.50.

    Reuters·
    US
    FDMT
    +0.88%
    Reuters·
    US
    FDMT
    +0.88%

    Otsuka’s Sibeprenlimab Shows Promising Results in IgAN Treatment

    Otsuka Holdings Co. announced promising 12-month interim results from its Phase 3 VISIONARY trial for sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN), showing significant reduction in proteinuria and a favorable safety profile. The company has filed a Biologics License Application with the U.S. FDA, receiving a Priority Review designation. The latest analyst rating for Otsuka's stock (JP:4578) is a Buy with a price target of Yen9366.00. Current market cap stands at Yen4415.6B, with a year-to-date price performance of -1.84%.

    Tip Ranks·
    US
    OTSKY
    0.00%
    Tip Ranks·
    US
    OTSKY
    0.00%

    09:36 ET Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 months with Recor Medical's Paradise Ultrasound Renal Denervation System

    Recor Medical and Otsuka Medical Devices announced significant results from two clinical studies presented at the 2025 TCT conference. The Global Paradise System Registry showed a 19.6 mmHg reduction in office systolic blood pressure at six months with the Paradise Ultrasound Renal Denervation (uRDN) system. Additionally, a pooled analysis from the RADIANCE trials demonstrated a sustained 15.7 mmHg reduction at 24 months. The Paradise uRDN system is designed for patients with uncontrolled hypertension and is FDA approved for use in the U.S.

    prnewswire·
    US
    OTSKY
    0.00%
    prnewswire·
    US
    OTSKY
    0.00%

    4DMT and Otsuka to advance eye disease treatment in APAC

    4D Molecular Therapeutics (4DMT) has entered an exclusive license agreement with Otsuka Pharmaceutical to develop and market 4D-150, a treatment for retinal vascular conditions, including wet AMD and diabetic macular edema, in the Asia-Pacific region. Otsuka will pay $85 million upfront and commit at least $50 million for development costs through 2028, with potential milestone payments of up to $336 million. 4DMT will lead the global Phase III clinical program, while retaining rights to develop and market the therapy outside APAC.

    Pharmaceutical Technology·
    US
    FDMT
    +0.88%
    Pharmaceutical Technology·
    US
    FDMT
    +0.88%